UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

Cancer medicine (Malden, MA), 2021-09, Vol.10 (18), p.6336-6343

2021

Volltextzugriff (PDF)

Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma

Bone marrow transplantation (Basingstoke), 2024-10

2024

Volltextzugriff (PDF)

Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma

Bone marrow transplantation (Basingstoke), 2024-10, Vol.59 (10), p.1440-1448

2024

Volltextzugriff (PDF)

Future pharmacoeconomic criteria for the treatment of infections

International journal of antimicrobial agents, 2009-07, Vol.34, p.S12-S14

Milkovich, Gary

2009

Volltextzugriff (PDF)

A Retrospective Record Review of Mobilization Strategies with and without Plerixafor for Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.5634-5634

2019

Volltextzugriff (PDF)

Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis

Bone marrow transplantation (Basingstoke), 2018-03, Vol.53 (3), p.246-254

2018

Volltextzugriff (PDF)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs

Bone marrow transplantation (Basingstoke), 2019-01, Vol.54 (1), p.123-129

2019

Volltextzugriff (PDF)

MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S502-S502

2023

Volltextzugriff (PDF)

P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S98-S98

2023

Volltextzugriff (PDF)

POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S221-S221

2023

Volltextzugriff (PDF)

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Clinical lymphoma, myeloma and leukemia, 2024-01, Vol.24 (1), p.55-63

2024

Volltextzugriff (PDF)

Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective

Transplant international, 2017-10, Vol.30 (10), p.1011-1019

2017

Volltextzugriff (PDF)

A clinician’s guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria

The American journal of medicine, 2005-07, Vol.118 (7), p.1-6

2005

Volltextzugriff (PDF)

Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention

American journal of health-system pharmacy, 2003-07, Vol.60 (suppl 3), p.S15-S21

2003

Volltextzugriff (PDF)

Intravenous-to-Oral Transition Therapy in Community-Acquired Pneumonia: The INOVA Health System Experience

Pharmacotherapy, 2001-07, Vol.21 (7P2), p.83S-88S

Milkovich, Gary

2001

Volltextzugriff (PDF)

Intravenous-to-oral transition therapy in community-acquired pneumonia : The INOVA Health System experience: Optimizing antiinfective transition therapy in community-acquired pneumonia

Pharmacotherapy, 2001, Vol.21 (7), p.83S-88S

MILKOVICH, Gary

2001

Volltextzugriff (PDF)

Adverse Events Associated with Commonly Used Cancer Regimens

Pharmacotherapy, 2000-07, Vol.20 (7P2), p.126S-128S

MILKOVICH, Gary

2000

Volltextzugriff (PDF)

The role of the hospital pharmacist in cost control and antibiotic policy

International journal of antimicrobial agents, 2000-11, Vol.16 (3), p.291-294

Milkovich, Gary

2000

Volltextzugriff (PDF)

Respiratory tract infections : at-risk patients, who are they? Implications for their management with levofloxacin

International journal of antimicrobial agents, 2006-09, Vol.28, p.S115-S127

2006

Volltextzugriff (PDF)

Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention: Clinical and economic implications of bleeding after percutaneous coronary intervention

American journal of health-system pharmacy, 2003, Vol.60, p.S15-S21

2003

Volltextzugriff (PDF)

Adverse Events Associated with Commonly Used Cancer Regimens

Pharmacotherapy, 2000-07, Vol.20 (7P2), p.95S-95S

Milkovich, Gary

2000

Volltextzugriff (PDF)

Respiratory tract infections: at-risk patients, who are they?

International journal of antimicrobial agents, 2006, Vol.28, p.S115-S127

2006

Volltextzugriff (PDF)

Impact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction

Pharmacotherapy, 2003-12, Vol.23 (12P2), p.101S-109S

2003

Volltextzugriff (PDF)

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia

Current medical research and opinion, 2004-09, Vol.20 (9), p.1473-1481

2004

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(21)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Pharmacology & Pharmacy
(12)
Female
(10)
Male
(10)
Pharmacology. Drug Treatments
(10)
Middle Aged
(8)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(7)
Aged
(6)
Anti-Bacterial Agents - Economics
(6)
Oncology
(6)
Adult
(5)
Antibacterial Agents
(5)
Cost-Benefit Analysis
(5)
Hematology
(5)
Levofloxacin
(5)
Transplantation
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma

Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma

Future pharmacoeconomic criteria for the treatment of infections

A Retrospective Record Review of Mobilization Strategies with and without Plerixafor for Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs

MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study

POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective

A clinician’s guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria

Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention

Intravenous-to-Oral Transition Therapy in Community-Acquired Pneumonia: The INOVA Health System Experience

Intravenous-to-oral transition therapy in community-acquired pneumonia : The INOVA Health System experience: Optimizing antiinfective transition therapy in community-acquired pneumonia

Adverse Events Associated with Commonly Used Cancer Regimens

The role of the hospital pharmacist in cost control and antibiotic policy

Respiratory tract infections : at-risk patients, who are they? Implications for their management with levofloxacin

Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention: Clinical and economic implications of bleeding after percutaneous coronary intervention

Adverse Events Associated with Commonly Used Cancer Regimens

Respiratory tract infections: at-risk patients, who are they?

Impact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia

Suchergebnisse filtern